2021
DOI: 10.1016/j.addr.2021.113930
|View full text |Cite
|
Sign up to set email alerts
|

Advances in mRNA non-viral delivery approaches

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
84
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 75 publications
(84 citation statements)
references
References 117 publications
0
84
0
Order By: Relevance
“…Also, at the 7th position, guanine nucleotide will be methylated by methyltransferase, which is why the cap is known as a 7-methyl guanylate cap (m7G). Thus, the 5′ cap plays a primary role in producing, regulating mature mRNA, serving as a ribosomal recognition sign, and ensuring mRNA stability during the translation process [ 128 ].
Fig.
…”
Section: Transdermal Delivery Of Specific Genetic Materialsmentioning
confidence: 99%
“…Also, at the 7th position, guanine nucleotide will be methylated by methyltransferase, which is why the cap is known as a 7-methyl guanylate cap (m7G). Thus, the 5′ cap plays a primary role in producing, regulating mature mRNA, serving as a ribosomal recognition sign, and ensuring mRNA stability during the translation process [ 128 ].
Fig.
…”
Section: Transdermal Delivery Of Specific Genetic Materialsmentioning
confidence: 99%
“…Nucleic acid-based drugs generally enter cells via endocytosis; most of these therapeutics must be formulated as a bioconjugate to facilitate receptor-mediated endocytosis and/or increase their lipophilicity [36][37][38] (Figure 2B). For example, conjugation of an siRNA with anandamide, folate, or cholesterol enables efficient uptake of the siRNA by cells, likely via the corresponding conjugate-specific receptor [39].…”
Section: Bioconjugations Of Asosmentioning
confidence: 99%
“…Oligonucleotide bioconjugates offer the potential for enhanced drug delivery, but recent advances in nanotechnology have further benefited the transport of therapeutic ASOs across biological barriers and improved their pharmacokinetics in circulating blood. Several nanoparticle-mediated delivery systems have been developed [15,18,[36][37][38] (Figure 2C).…”
Section: Vehicle-mediated Delivery Of Asosmentioning
confidence: 99%
“…They are subjected to significant limitations concerning immunogenicity and toxicity [ 120 ]. Although a lot of efforts have been made in order to eliminate these challenges, e.g., by using mutant vectors, self-inactivating vectors, nonsegmented negative-stranded (NSNS) viruses, such as Sendai virus (SeV) [ 119 , 121 , 122 ], the superiority of non-viral vectors for mRNA delivery is still integral [ 12 , 123 ].…”
Section: Formulation Strategiesmentioning
confidence: 99%